Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone

Main Article Content

Anastasia O Kurta
Leonard B Weinstock
Natalie Semchyshyn


erythromelalgia, mast cells, mast cell activation syndrome, MCAS naltrexone, low dose naltrexone


Erythromelalgia is a rare condition that may be associated with a variety of underlying conditions and can be refractory to therapy. We report a case of a patient with mast cell activation syndrome (MCAS) who developed erythromelalgia and responded to low dose naltrexone (LDN).


1. Thompson GH, Hahn G, Rang M. Erythromelalgia. Clin Orthop Relat Res. 1979;144:249-254.

2. Reed KB, Davis MD. Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2009;23:13. doi: 10.1111/j.1468-3083.2008.02938.x.

3. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171-174.

4. Molderings GJ, Haenisch B, Bogdanow M, et al. Familial occurrence of systemic mast cell activation disease. PLoS One. 2013;8(9):e76241. doi:10.1371/journal.pone.0076241.10.

5. Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease – a guide to diagnosis and therapeutic options. Ann Med. 2016;48:190-201.

6. Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey-Hailey disease with low-dose naltrexone. JAMA Dermatol. 2017;153(10):1018-1020. doi: 10.1001/jamadermatol.2017.2446.

7. Weinstock LB, Myers TL, Steinhoff M, Smith JP. Successful treatment of adult-onset dermatitis herpetiformis with low dose naltrexone. J Med Case Studies. 2017;2(3):27-29.

8. Weinstock LB, Egeberg A, Cottel J, Aldridge L. Low dose naltrexone therapy for psoriasis: open-label case series. SPIN 2019 Abstract: P193


10. McLaughlin PJ, Zagon IS. Duration of opioid receptor blockade determines biotherapeutic response. Biochem Pharmacol. 2015;97:236-46. doi: 10.1016/j.bcp.2015.06.016.

11. Bruno K, Woller SA, Miller Y, et al. Tarteting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states. Pain. 2018;159:1908-1915. doi: 10.1097/j.pain.0000000000001306.

12. Zhang X, Wang Y, Dong H, et al. Induction of Microglial Activation by Mediators Released from Mast Cells. Cell Physiol Biochem. 2016;38:1520-1531. doi: 10.1159/000443093. Epub 2016 Apr 7.